Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription 10.06.2024 1 BMJ 2 J Virol 1 Lancet 1 Nat Immunol 1 Pediatr Infect Dis J 1 PLoS Med 4 PLoS One 14 Vaccine 1 Virus Res

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMJ

1. MAHASE E
   NHS England launches scheme to boost signups for personalised cancer vaccine trials.
   BMJ. 2024;385:q1212.
   PubMed        
   
   

   
   J Virol

2. BOOPATHY AV, Nekkalapudi A, Sung J, Schulha S, et al
   Flt3 agonist enhances immunogenicity of arenavirus vector-based simian immunodeficiency virus vaccine in macaques.
   J Virol. 2024 Jun 3:e0029424. doi: 10.1128/jvi.00294.
   PubMed         Abstract available
   
   
3. LU J, Liu J, Wu Y, He X, et al
   A full-length glycoprotein mRNA vaccine confers complete protection against severe fever with thrombocytopenia syndrome virus, with broad-spectrum protective effects against bandaviruses.
   J Virol. 2024 Jun 3:e0076924. doi: 10.1128/jvi.00769.
   PubMed         Abstract available
   
   

   
   Lancet

4. ASHINZE P, Mafua N, Obafemi E
   Nigeria rolls out novel meningitis vaccine.
   Lancet. 2024;403:2373.
   PubMed        
   
   

   
   Nat Immunol

5. RAY R, Schiffner T, Wang X, Yan Y, et al
   Affinity gaps among B cells in germinal centers drive the selection of MPER precursors.
   Nat Immunol. 2024;25:1083-1096.
   PubMed         Abstract available
   
   

   
   Pediatr Infect Dis J

6. KAUR R, Schulz S, Sherman A, Andrejko K, et al
   Anticipated Effects of Higher-valency Pneumococcal Conjugate Vaccines on Colonization and Acute Otitis Media.
   Pediatr Infect Dis J. 2024 Jun 5. doi: 10.1097/INF.0000000000004413.
   PubMed         Abstract available
   
   

   
   PLoS Med

7. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
   Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
   PLoS Med. 2024;21:e1004375.
   PubMed         Abstract available
   
   

   
   PLoS One

8. RIBEIRO LB, Gazzinelli A, Santiago HDC, Fiuza JA, et al
   Public engagement for the conduct of a controlled human infection study testing vaccines against Necator americanus (hookworm) in areas of active hookworm transmission in Brazil.
   PLoS One. 2024;19:e0299022.
   PubMed         Abstract available
   
   
9. SASSE K, Mahabir R, Gkountouna O, Crooks A, et al
   Understanding the determinants of vaccine hesitancy in the United States: A comparison of social surveys and social media.
   PLoS One. 2024;19:e0301488.
   PubMed         Abstract available
   
   
10. ARTEMCHUK O, Evlampidou I
    Knowledge, attitudes and practices survey towards pneumococcal infection and vaccination among primary health care physicians, Ukraine, 2021.
    PLoS One. 2024;19:e0304346.
    PubMed         Abstract available
    
    
11. GARG N, Tellier G, Vale N, Kluge J, et al
    Phase 1, randomized, rater and participant blinded placebo-controlled study of the safety, reactogenicity, tolerability and immunogenicity of H1N1 influenza vaccine delivered by VX-103 (a MIMIX microneedle patch [MAP] system) in healthy adults.
    PLoS One. 2024;19:e0303450.
    PubMed         Abstract available
    
    

    
    Vaccine

12. FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al
    Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over calendar time and by time since administration during prevalent circulation of different O
    Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
13. BEJKO D, Ernst C, Vergison A, Stranges S, et al
    High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
    Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
14. WOLFSCHMIDT-FIETKAU A, Goertz RS, Goertzen S, Schmid K, et al
    Immunity against vaccine-preventable diseases among pregnant employees in Germany. A situation analysis before the introduction of the Measles Protection Act.
    Vaccine. 2024 May 31:S0264-410X(24)00604-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
15. HE Q, Chen Y, Li Y, Cheng X, et al
    Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus.
    Vaccine. 2024 May 31:S0264-410X(24)00583-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
16. EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
    A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
    Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
17. COMER D, Warner NZ, Noone C
    Human PapillomaVirus vaccination in gay and bi men: Predictors, dynamic norms, and connectedness to the LGBT+ community.
    Vaccine. 2024 May 31:S0264-410X(24)00639-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
18. POVEDA-URKIXO I, Mena-Bueno S, Ramirez GA, Zabalza-Barangua A, et al
    Brucella melitensis Rev1Deltawzm: Placental pathogenesis studies and safety in pregnant ewes.
    Vaccine. 2024;42:3710-3720.
    PubMed         Abstract available
    
    
19. MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
    Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
    Vaccine. 2024;42:3647-3654.
    PubMed         Abstract available
    
    
20. FENG J, Du Y, Chen L, Su W, et al
    A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
    Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
21. GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
    Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
    Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
22. KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al
    Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
    Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
23. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
    Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
24. KANG DW, June Choe Y, Lee JY, Suk IA, et al
    Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Vaccine. 2024 Jun 5:S0264-410X(24)00616-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
25. YOUNES S, Nicolai E, Younes N, Pieri M, et al
    Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

    
    Virus Res

26. JALILVAND S, Latifi T, Kachooei A, Mirhoseinian M, et al
    Circulating rotavirus strains in children with acute gastroenteritis in Iran, 1986 to 2023 and their genetic/antigenic divergence compared to approved vaccines strains (Rotarix, RotaTeq, ROTAVAC, ROTASIIL) before mass vaccination: Clues for vaccinatio
    Virus Res. 2024;346:199411.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.